{"id":"01448","slug":"use-of-immunomodulatory-dna--01448","source":{"id":"01448","dataset":"techtransfer","title":"Use of Immunomodulatory DNA for the Treatment of Diseases of Systemic Sepsis","description_":"<p><h2>Description</h2>This invention is the discovery that within the intestinal mucosa, activation of the TLR9 immune receptor with de-methylated bacterial DNA (CPG-DNA) suppresses TLR4-mediated signaling. Suppression of TLR4 activity appears to signifi­cantly reduce the severity of necrotizing entero­colitis (NEC) and mucosal inflammation. TLR4 plays a critical role in the pathogenesis of NEC. This discovery would benefit patients with NEC or those at risk of developing NEC (essentially all premature infants) by acting as a selective immuno-modulator, thereby preventing the progression of the disease. This invention represents a novel strat­egy by which modulation of the innate immune system leads to attenuation of experimental NEC. TLR4 mediated signaling and cytokine release in enterocytes is attenuated by the TLR9 ligand, CpG-DNA in vitro and in vivo. TLR9 inhibits TLR4 signaling in enterocytes through effects on receptor localization.</p><p></p><p></p><p></p><p><h2>IP Status</h2><a target=\"_blank\" href=\"https://patents.google.com/patent/US8518905B2\">https://patents.google.com/patent/US8518905B2</a></p><p></p>","tags":[],"file_number":"01448","collections":[],"meta_description":"TLR9-activated CpG-DNA modulates innate immunity to dampen TLR4 signaling, reducing NEC severity and intestinal inflammation.","image_url":"","apriori_judge_output":"{\"scores\":{\"novelty\":5.0,\"potential_impact\":4.0,\"readiness\":2.0,\"scalability\":3.0,\"timeliness\":2.0},\"weighted_score\":3.2,\"risks\":[\"Old leveraging IP (2007) with limited current data\",\"Preclinical to early clinical data; regulatory path uncertain\",\"Safety concerns for neonatal immunomodulation\",\"Manufacturability and delivery challenges in premature infants\",\"Market size and competition in NEC prevention/treatment\"],\"one_sentence_take\":\"High novelty with mechanistic insight but aging data and uncertain current readiness limit near-term impact; strong potential if updated validation and regulatory path are established.\"}","lead_inventor_name":"David Hackam","lead_inventor_dept":"Pediatric Surgery","technology_type":"Therapeutic Modality","technology_subtype":"Other Therapeutic Modality","therapeutic_areas":["Infectious Disease","Gastroenterology"],"therapeutic_indications":["Sepsis","Other"],"custom_tags":[],"all_tech_innovators":["Steven C. Gribar","David Joel Hackam"],"date_submitted":"2007-02-20"},"highlight":{},"matched_queries":null,"score":0.0}